
Oliver W Hakenberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11503294/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. European Urology Oncology, 2021, 4, 802-810.	5.4	22
2	Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. European Urology Oncology, 2021, 4, 121-123.	5.4	5
3	Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study. Urologia Internationalis, 2021, 105, 436-445.	1.3	1
4	Cure of Interstitial Cystitis and Non-Ulcerating Hunner's Ulcer by Cardinal/Uterosacral Ligament Repair. Urologia Internationalis, 2021, 105, 920-923.	1.3	6
5	Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. Urologia Internationalis, 2021, 105, 169-180.	1.3	37
6	Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II – Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy. Urologia Internationalis, 2021, 105, 181-191.	1.3	19
7	Flow-dependent differentiation of cultured adrenal cells under different stimuli. Cell and Tissue Research, 2021, 384, 325-331.	2.9	Ο
8	Ceruloplasmin expression in renal cell carcinoma correlates with higher-grade and shortened survival. Biomarkers in Medicine, 2021, 15, 841-850.	1.4	1
9	Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 838.e7-838.e13.	1.6	3
10	A risk calculator predicting recurrence in lymph node metastatic penile cancer. BJU International, 2020, 126, 577-585.	2.5	12
11	Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with nodeâ€positive penile squamous cell carcinoma. BJU International, 2020, 125, 867-875.	2.5	15
12	Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications. Clinical Genitourinary Cancer, 2020, 18, e563-e572.	1.9	15
13	Lymph Node Management in Penile Cancer. , 2019, , 833-843.		Ο
14	Lymph Node Management in Penile Cancer. , 2019, , 1-11.		0
15	Diagnosis and Staging in Penile Cancer. , 2019, , 1-8.		Ο
16	Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 531.e7-531.e15.	1.6	27
17	Diagnosis and Staging in Penile Cancer. , 2019, , 807-815.		Ο
18	Penile Sparing Surgery for Penile Cancer: A Multicenter International Retrospective Cohort. Journal of Urology, 2018, 199, 1233-1237.	0.4	59

#	Article	IF	CITATIONS
19	Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study. Urologia Internationalis, 2018, 101, 16-24.	1.3	28
20	Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. European Urology, 2018, 74, 76-83.	1.9	61
21	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node–Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score–Weighted Competing Risks Analysis. European Urology Focus, 2018, 4, 252-259.	3.1	18
22	E2F1 Signalling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers. European Urology Focus, 2018, 4, 599-607.	3.1	14
23	Surgical management of penile carcinoma <i>in situ</i> : results from an international collaborative study and review of the literature. BJU International, 2018, 121, 393-398.	2.5	45
24	Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 11.e1-11.e6.	1.6	9
25	Periâ€operative allogeneic blood transfusion does not adversely affect oncological outcomes after radical cystectomy for urinary bladder cancer: a propensity scoreâ€weighted European multicentre study. BJU International, 2018, 121, 101-110.	2.5	21
26	Laser ablation as monotherapy for penile squamous cell carcinoma: A multi-center cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 147-152.	1.6	26
27	Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy. BMC Urology, 2018, 18, 91.	1.4	12
28	Copy Number Alterations with Prognostic Potential in Clear Cell Renal Cell Carcinoma. Urologia Internationalis, 2018, 101, 417-424.	1.3	8
29	Gender and Mortality after Radical Cystectomy: Competing Risk Analysis. Urologia Internationalis, 2018, 101, 293-299.	1.3	9
30	Cross-Sectional Patient-Reported Outcome Measuring of Health-Related Quality of Life With Establishment of Cancer- and Treatment-Specific Functional and Symptom Scales in Patients With Penile Cancer. Clinical Genitourinary Cancer, 2018, 16, e1215-e1220.	1.9	14
31	Pathology, Molecular Biology, and Prognosis of Penile Squamous Cell Carcinoma: What Can We Learn from the Specimen?. European Urology Supplements, 2018, 17, 138-145.	0.1	1
32	Hyperpolarization-Activated Cyclic Nucleotide-Gated Non-selective (HCN) Ion Channels Regulate Human and Murine Urinary Bladder Contractility. Frontiers in Physiology, 2018, 9, 753.	2.8	19
33	Re: Differences in Survival Associated with Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. European Urology, 2018, 74, 678-679.	1.9	1
34	A brief overview of the development of robot-assisted radical prostatectomy. Arab Journal of Urology Arab Association of Urology, 2018, 16, 293-296.	1.5	19
35	Analysis of psychosocial stress factors in patients with renal cancer. Therapeutic Advances in Urology, 2018, 10, 175-182.	2.0	18
36	Critical evaluation of the PADUA score in a retrospective analysis of open partial nephrectomy. Turkish Journal of Urology, 2018, 44, 208-212.	1.3	7

#	Article	IF	CITATIONS
37	Urinmarker beim Blasenkarzinom. , 2018, , 135-152.		ο
38	Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. World Journal of Urology, 2017, 35, 245-250.	2.2	8
39	Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1757-1769.	2.5	14
40	Identifying Psychosocial Distress and Stressors Using Distress-screening Instruments in Patients With Localized and Advanced Penile Cancer. Clinical Genitourinary Cancer, 2017, 15, 605-609.	1.9	19
41	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. Clinical Genitourinary Cancer, 2017, 15, e809-e817.	1.9	21
42	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clinical Genitourinary Cancer, 2017, 15, 548-555.e3.	1.9	37
43	Psychological stress in geriatric patients with genito-urinary cancers. Journal of Geriatric Oncology, 2017, 8, 216-219.	1.0	6
44	Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis. Acta Neuropathologica, 2017, 134, 905-922.	7.7	12
45	Glansectomy as Primary Management of Penile Squamous Cell Carcinoma: An International Study Collaboration. Urology, 2017, 109, 140-144.	1.0	15
46	Nivolumab for the treatment of bladder cancer. Expert Opinion on Biological Therapy, 2017, 17, 1309-1315.	3.1	13
47	Upper Urinary Tract Tumors: Which Diagnostic Methods Are Needed?. Urologia Internationalis, 2017, 98, 304-311.	1.3	15
48	Level of education and mortality after radical prostatectomy. Asian Journal of Andrology, 2017, 19, 173.	1.6	5
49	P2Y receptor-mediated transient relaxation of rat longitudinal ileum preparations involves phospholipase C activation, intracellular Ca2+ release and SK channel activation. Acta Pharmacologica Sinica, 2016, 37, 617-628.	6.1	7
50	Aggressive Angiomyxoma as a Rare Differential Diagnosis of Enlargement of the Scrotum. Clinical Genitourinary Cancer, 2016, 14, e237-e239.	1.9	9
51	Expression and clinicopathological correlations of retinoid acid receptor responder protein 1 in renal cell carcinomas. Biomarkers in Medicine, 2016, 10, 721-732.	1.4	5
52	Re: Role of Human Papillomavirus in Penile Carcinomas Worldwide. European Urology, 2016, 70, 1078-1079.	1.9	1
53	Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy - A Prospective Multicenter Study. Urologia Internationalis, 2016, 96, 57-64.	1.3	8
54	Integrated Loss of miR-1/miR-101/miR-204 Discriminates Metastatic from Nonmetastatic Penile Carcinomas and Can Predict Patient Outcome. Journal of Urology, 2016, 196, 570-578.	0.4	26

#	Article	IF	CITATIONS
55	Diagnostic and prognostic value of bladder cancer-related transcript markers in urine. Journal of Cancer Research and Clinical Oncology, 2016, 142, 401-414.	2.5	14
56	Decreased Overall and Bladder Cancer–Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis. European Urology, 2016, 69, 984-987.	1.9	27
57	Chemotherapy in Penile Cancer. , 2016, , 235-243.		0
58	Ageâ€related decrease of adenosineâ€mediated relaxation in rat detrusor is a result of A2B receptor downregulation. International Journal of Urology, 2015, 22, 322-329.	1.0	6
59	Inverse relationship of Rho kinase and myosin-light chain kinase expression in the aging human detrusor smooth muscle. BMC Urology, 2015, 15, 104.	1.4	8
60	Evidence from the â€~PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?. Annals of Surgical Oncology, 2015, 22, 1032-1042.	1.5	33
61	Reply to Kamran Zargar-Shoshtari, Pranav Sharma and Philippe E. Spiess' Letter to the Editor re: Oliver W. Hakenberg, Eva M. Compérat, Suks Minhas, Andrea Necchi, Chris Protzel, Nick Watkin. EAU Guidelines on Penile Cancer: 2014 Update. Eur Urol 2015;67:142–50. European Urology, 2015, 67, e111.	1.9	3
62	Lee mortality index as comorbidity measure in patients undergoing radical cystectomy. SpringerPlus, 2015, 4, 55.	1.2	3
63	EAU Guidelines on Penile Cancer: 2014 Update. European Urology, 2015, 67, 142-150.	1.9	479
64	Age-dependent contribution of Rho kinase in carbachol-induced contraction of human detrusor smooth muscle in vitro. Acta Pharmacologica Sinica, 2014, 35, 74-81.	6.1	13
65	A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. BMC Urology, 2014, 14, 28.	1.4	20
66	Treatment of Bone Metastases in Urologic Malignancies. Urologia Internationalis, 2014, 93, 249-256.	1.3	18
67	Urinary immunocytology—Promise or nonseller? A review with an opinion. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 383-390.	1.6	6
68	Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (<scp>EpCAM</scp>) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays. BJU International, 2014, 114, 296-302.	2.5	29
69	C-kit overexpression is not associated with KIT gene mutations in chromophobe renal cell carcinoma or renal oncocytoma. Pathology Research and Practice, 2014, 210, 521-525.	2.3	14
70	Chemotherapy in Penile Cancer. , 2014, , 199-214.		0
71	Peniskarzinom. , 2014, , 1-17.		0
72	Kiâ€67, miniâ€chromosome maintenance 2 protein (<scp>MCM2</scp>) and geminin have no independent prognostic relevance for cancerâ€specific survival in surgically treated squamous cell carcinoma of the penis. BJU International, 2013, 112, E383-90.	2.5	22

#	Article	IF	CITATIONS
73	Which comorbidity classification best fits elderly candidates for radical prostatectomy?. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 461-467.	1.6	14
74	Inherent Grading Characteristics of Individual Pathologists Contribute to Clinically and Prognostically Relevant Interobserver Discordance Concerning Broders' Grading of Penile Squamous Cell Carcinomas. Urologia Internationalis, 2013, 90, 207-213.	1.3	22
75	C-MET is expressed in the majority of penile squamous cell carcinomas and correlates with polysomy-7 but is not associated with MET oncogene amplification, pertinent histopathologic parameters, or with cancer-specific survival. Pathology Research and Practice, 2013, 209, 215-220.	2.3	11
76	Systematic Assessment of Complications and Outcome of Radical Cystectomy Undertaken with Curative Intent in Patients with Comorbidity and over 75 Years of Age. Urologia Internationalis, 2013, 90, 195-201.	1.3	20
77	Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. Journal of Clinical Pathology, 2012, 65, 232-236.	2.0	69
78	Chemotherapy in penile cancer. Therapeutic Advances in Urology, 2012, 4, 133-138.	2.0	23
79	p16 ^{INK4a} is a Marker of Good Prognosis for Primary Invasive Penile Squamous Cell Carcinoma: A Multi-Institutional Study. Journal of Urology, 2012, 187, 899-907.	0.4	68
80	Follow-up After Surgical Treatment of Bladder Cancer: A Critical Analysis of the Literature. European Urology, 2012, 62, 290-302.	1.9	121
81	Which patients are at the highest risk of dying from competing causes â‰⊉O years after radical prostatectomy?. BJU International, 2012, 110, 206-210.	2.5	24
82	Urine Markers for Detection and Surveillance of Non–Muscle-Invasive Bladder Cancer. European Urology, 2011, 60, 484-492.	1.9	176
83	Alterations in the tumor suppressor gene p16 INK4A are associated with aggressive behavior of penile carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 221-229.	2.8	90
84	Correlation of Pathological and Cytological-Cytometric Grading of Transitional Cell Carcinoma of the Urinary Tract. Urologia Internationalis, 2011, 86, 36-40.	1.3	7
85	Different HER2 Protein Expression Profiles Aid in the Histologic Differential Diagnosis Between Urothelial Carcinoma In Situ (CIS) and Non-CIS Conditions (Dysplasia and Reactive Atypia) of the Urinary Bladder Mucosa. American Journal of Clinical Pathology, 2011, 136, 881-888.	0.7	18
86	Re: Niels M. Graafland, Joost A.P. Leijte, Renato A. Valdés Olmos, et al. Scanning with 18F-FDG-PET/CT for Detection of Pelvic Nodal Involvement in Inguinal Node-Positive Penile Carcinoma. Eur Urol 2009;56:339–45. European Urology, 2010, 57, e12-e13.	1.9	2
87	Prevention and Management of Complications Following Radical Cystectomy for Bladder Cancer. European Urology, 2010, 57, 983-1001.	1.9	194
88	Laparoscopic Living-Donor Nephrectomy: Analysis of the Existing Literature. European Urology, 2010, 58, 498-509.	1.9	119
89	Survival analysis in men undergoing radical prostatectomy at an age of 70 years or older. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 628-634.	1.6	10
90	Emerging apoptosis agonists for bladder cancer. Expert Opinion on Emerging Drugs, 2009, 14, 607-618.	2.4	6

#	Article	IF	CITATIONS
91	A New Neoadjuvant Chemotherapy Regimen for Penile Cancer with Nodal Metastases: A Step Forward. European Urology, 2009, 55, 552-553.	1.9	3
92	Lymphadenectomy in the Surgical Management of Penile Cancer. European Urology, 2009, 55, 1075-1088.	1.9	201
93	Re: Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumour Marker. European Urology, 2009, 56, 1087-1088.	1.9	0
94	How to Make the Diagnosis of Benign Prostatic Disease. European Urology Supplements, 2009, 8, 490-495.	0.1	5
95	Detailed Analysis of Charlson Comorbidity Score as Predictor of Mortality After Radical Prostatectomy. Urology, 2008, 72, 1252-1257.	1.0	34
96	Interaction Between Age and Comorbidity as Predictors of Mortality After Radical Prostatectomy. Journal of Urology, 2008, 179, 1823-1829.	0.4	15
97	Comment on Di Silverio et al.: Neodajuvant Therapy with Sorafenib in Advanced Renal Cell Carcinoma with Vena Cava Extension Submitted to Radical Nephrectomy. Urologia Internationalis, 2008, 80, 454-454.	1.3	3
98	Molecular Therapy in Urologic Oncology. Urologia Internationalis, 2007, 79, 1-7.	1.3	20
99	Comparative Diagnostic Value of Urine Cytology, UBC-ELISA, and Fluorescence In Situ Hybridization for Detection of Transitional Cell Carcinoma of Urinary Bladder in Routine Clinical Practice. Urology, 2007, 70, 449-453.	1.0	38
100	Changing comorbidity classification patterns at radical prostatectomy during a 10-year period. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 26-31.	1.6	3
101	Contribution of Ca2+ influx to carbachol-induced detrusor contraction is different in human urinary bladder compared to pig and mouse. European Journal of Pharmacology, 2007, 565, 180-189.	3.5	40
102	Perioperative Complications of Radical Cystectomy in a Contemporary Series. European Urology, 2007, 51, 397-402.	1.9	244
103	Synthetic Nucleic Acids as Potential Therapeutic Tools for Treatment of Bladder Carcinoma. European Urology, 2007, 51, 315-327.	1.9	11
104	Editorial Comment on: A Prospective Randomized Study Comparing Monopolar and Bipolar Transurethral Resection of Prostate Using Transurethral Resection in Saline (TURIS) System. European Urology, 2007, 52, 523.	1.9	2
105	Optimal treatment of locally advanced prostate cancer. World Journal of Urology, 2007, 25, 169-176.	2.2	20
106	Urinmarker und zellbasierte Nachweisverfahren beim Urothelkarzinom. , 2007, , 135-155.		0
107	Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Letters, 2006, 232, 243-254.	7.2	50
108	Comorbidity is poor predictor of survival in patients undergoing radical prostatectomy after 70 years of age. Urology, 2006, 68, 583-586.	1.0	14

#	Article	IF	CITATIONS
109	Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU International, 2006, 98, 1225-1227.	2.5	105
110	Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 374, 87-97.	3.0	41
111	Treatment of Locally Advanced Prostate Cancer – The Case for Radical Prostatectomy. Urologia Internationalis, 2006, 77, 193-199.	1.3	14
112	Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. British Journal of Pharmacology, 2005, 145, 608-619.	5.4	42
113	Feasibility and Limitations of Comorbidity Measurement in Patients Undergoing Radical Prostatectomy. European Urology, 2005, 47, 190-195.	1.9	26
114	Re: Froehner M, Koch R, Litz RJ, Oehlschlaeger S, Hakenberg OW, Wirth MP, Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy. Eur Urol 2005;47:190–5. European Urology, 2005, 48, 169.	1.9	0
115	Reply to M.G. Clarke, R. MacDonagh. European Urology, 2005, 48, 170.	1.9	Ο
116	Effect of rilmakalim on detrusor contraction in the presence and absence of urothelium. Naunyn-Schmiedeberg's Archives of Pharmacology, 2005, 372, 203-212.	3.0	20
117	CHOLINERGIC AND PURINERGIC RESPONSES IN ISOLATED HUMAN DETRUSOR IN RELATION TO AGE. Journal of Urology, 2005, 173, 2182-2189.	0.4	39
118	Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology, 2004, 64, 1121-1126.	1.0	47
119	Chronic Pelvic Painin Men. Urologia Internationalis, 2002, 68, 138-143.	1.3	17
120	Spontaneous late rupture of orthotopic detubularized ileal neobladders: report of five cases. Urology, 2001, 58, 43-46.	1.0	30
121	Is There a Relationship between the Amount of Tissue Removed at Transurethral Resection of the Prostate and Clinical Improvement in Benign Prostatic Hyperplasia. European Urology, 2001, 39, 412-417.	1.9	41
122	Relationship of Comorbidity, Age and Perioperative Complications in Patients Undergoing Radical Prostatectomy. Urologia Internationalis, 2001, 67, 283-288.	1.3	20
123	Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement. Neurourology and Urodynamics, 2000, 19, 585-593.	1.5	146
124	Locally Recurrent Malignant Fibrous Histiocytoma: A Rare and Aggressive Genitourinary Malignancy. Urologia Internationalis, 1999, 62, 164-170.	1.3	22
125	Issues in the Treatment of Penile Carcinoma. Urologia Internationalis, 1999, 62, 229-233.	1.3	27
126	Brachytherapy for Prostate Cancer. Urologia Internationalis, 1999, 63, 87-91.	1.3	11

#	Article	IF	CITATIONS
127	Does Evaluation With the International Prostate Symptom Score Predict the Outcome of Transurethral Resection of the Prostate?. Journal of Urology, 1997, 158, 94-99.	0.4	43
128	The Estimation of Bladder Volume by Sonocystography. Journal of Urology, 1983, 130, 249-251.	0.4	100